menu
    • menu
    [{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"EP0089-101","moa":"CNTN4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"GENA-104","moa":"CNTN4","graph1":"Oncology","graph2":"Phase I","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ellipses Pharma \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Ellipses Pharma \/ Ellipses Pharma"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"The Institute of Cancer Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Ellipses Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Ellipses Pharma"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP0042","moa":"FLT3\/Aurora kinase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vosilasarm","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vosilasarm","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Divestment","leadProduct":"Vosilasarm","moa":"NR3C4","graph1":"Oncology","graph2":"Phase I","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Ellipses Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Ellipses Pharma \/ Ellipses Pharma"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Kelun-Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Kelun-Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Kelun-Biotech"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"EP0031","moa":"RET receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"EP0057","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ellipses Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ellipses Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"EP0057","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Ellipses Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ellipses Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ellipses Pharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Ellipses Pharma

    Menu

    Ellipses Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0089-101

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Tolerability of EP0089

                            Details : EP0089-101 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 22, 2025

                            Lead Product(s) : EP0089-101

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GENA-104

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Genome & Company

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ellipses In-Licences GENA-104 A Novel Immuno-Oncology Agent

                            Details : Under the licensing agreement with Genome, Ellipses will take responsibility for all future clinical development of EP0089 (GENA-104) for the treatment of cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            February 11, 2025

                            Lead Product(s) : GENA-104

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Genome & Company

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ellipses Launches Pioneering Clinical Trial Programme in Middle East

                            Details : EP0031 is a potent next-generation selective RET inhibitor is being investigated for the potential treatment of RET-fusion positive non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 23, 2024

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ellipses' Next Generation Selective RET Inhibitor EP0031/A400 Cleared to Start Phase 2

                            Details : EP0031 is a potent next-generation selective RET inhibitor that has been granted fast track designation by the FDA for the potential treatment of RET-fusion positive non-small cell lung cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 01, 2024

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Kelun-Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma Announces Intent to Accelerate Clinical Programme Following ‘Encouraging’ Data on Next Gen...

                            Details : EP0031 is a potent next generation SRI with broad activity against common RET-altered tumour and mutations, including solvent front resistance mutations.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 05, 2023

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Kelun-Biotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0042

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma: EP0042 Receives Orphan Drug Designation from the US Food and Drug Administration

                            Details : EP0042 is a dual FLT3 and aurora kinase inhibitor under development as a new treatment for AML patients who have developed FLT3 inhibitor resistance. Aurora kinase has been shown to overcome acquired resistance to selective FLT3 inhibition both in vitro ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 14, 2023

                            Lead Product(s) : EP0042

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0042

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma Announces FDA Approval of IND Application for EP0042 for Patients With Acute Myeloid Leukaemia

                            Details : EP0042 is a dual FLT3 and Aurora kinase inhibitor under development as a new treatment for AML patients who have developed FLT3 inhibitor resistance. Aurora kinase has been shown to overcome acquired resistance to selective FLT3 inhibition both in vitro ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2023

                            Lead Product(s) : EP0042

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ellipses Announces First Patient Dosed with EP0031, a Next Generation Selective RET Inhibitor

                            Details : EP0031 is an SRI which aims to address the unmet need for patients with RET-altered tumours (Non-Small Cell Lung Cancer (NSCLC), medullary thyroid and other RET-altered tumours) who have progressed on first generation SRIs.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 14, 2022

                            Lead Product(s) : EP0031

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ellipses Pharma Presents Design of Newly Initiated Phase 1/2a Trial of Vosilasarm (EP0062) at SABCS

                            Details : EP0062 (vosilasarm) is an oral, non-steroidal, selective androgen receptor modulator (SARM) currently being developed for the treatment of AR+/HER2-/ER+ advanced breast cancer.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 02, 2022

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Ellipses Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or...

                            Details : Vosilasarm is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 10, 2022

                            Lead Product(s) : Vosilasarm

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth